Idiosyncratic Drug-induced Liver Injury Study

Formerly: Hepatic Adverse Drug Reactions Study

The international Drug-induced Liver Injury Consortium (iDILIC), a multi-national research group led jointly by Professor Ann Daly, Newcastle University and Dr Guruprasad Aithal, Nottingham Digestive Diseases Centre: NIHR Biomedical Research Unit is studying the genetic susceptibility to idiosyncratic drug-induced liver injury. The UK arm of the study, DILIGEN, is a portfolio study adopted by Comprehensive Local Research Networks (CLRN) nationally.

The study, involves collecting DNA from cases and suitable controls for a genome wide association study (GWAS) with the aim of identifying polymorphisms predictive of the development of drug-related liver injury and hence allowing the possibility of prevention. We will be grateful to physicians treating idiosyncratic drug-induced liver injury cases, particularly BSG members, to put us in contact with suitable patients.

Patient who developed one of the following due to drug-induced liver injury are suitable to be included:

  • >5-fold elevation above the upper limit of normal (ULN) of alanine transaminase (ALT) (or aspartate transaminase; AST when ALT is unavailable)
  • >2-fold elevation above the ULN for alkaline phosphatase (ALP) (when there is no bony cause for rise in ALP)
  • >3-fold elevation in ALT plus bilirubin elevation exceeding 2x UL

If any patients under your care either in the past or currently have suffered drug-induced liver injury relating to any prescribed drug, please contact our Research Nurse, Suzanne Henry, on the following telephone number: 0115 9249924 x  64415; Mobile Number 07595284870 or email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it . We will send you a letter to send to the potential case together with a patient information sheet which includes a form to indicate interest in the study. If the patient then returns the form to us, we will then arrange with your CLRN for a research nurse to visit him/her to collect a blood sample or saliva for DNA preparation.

View Full Protocol... [ 52 Kb ]